Stimulant medication and symptom interrelations in children, adolescents and adults with attention-deficit/hyperactivity disorder.
Saved in:
| Title: | Stimulant medication and symptom interrelations in children, adolescents and adults with attention-deficit/hyperactivity disorder. |
|---|---|
| Authors: | van der Pal, Zarah, Geurts, Hilde M., Haslbeck, Jonas M. B., van Keeken, Alex, Bruijn, Anne Marijn, Douw, Linda, van Rooij, Daan, Franke, Barbara, Buitelaar, Jan, Lambregts-Rommelse, Nanda, Hartman, Catharina, Oosterlaan, Jaap, Luman, Marjolein, Reneman, Liesbeth, Hoekstra, Pieter J., Blanken, Tessa F., Schrantee, Anouk |
| Source: | European Child & Adolescent Psychiatry. Jun2025, Vol. 34 Issue 6, p1917-1929. 13p. |
| Subjects: | Attention-deficit hyperactivity disorder, Central nervous system stimulants, Descriptive statistics, Psychopharmacology, Symptoms, Adolescence, Children, Adults |
| Abstract: | Stimulant medication is effective in alleviating overall symptom severity of attention-deficit/hyperactivity disorder (ADHD), yet interindividual variability in treatment response and tolerability still exists. While network analysis has identified differences in ADHD symptom relations, the impact of stimulant medication remains unexplored. Increased understanding of this association could provide valuable insights for optimizing treatment approaches for individuals with ADHD. In this study, we compared and characterized ADHD symptom networks (including 18 ADHD symptoms) between stimulant-treated (n = 348) and untreated (n = 70) individuals with ADHD and non-ADHD controls (NACs; n = 444). Moreover, we compared symptom networks between subgroups defined by their stimulant treatment trajectory (early-and-intense use, late-and-moderate use). Stimulant-treated individuals with ADHD showed stronger associations between symptoms, compared with untreated individuals with ADHD and NACs. We found no differences in symptom networks between the stimulant treatment trajectory subgroups. Prospective longitudinal studies are needed to disentangle whether the identified differences stem from treatment or pre-existing factors. [ABSTRACT FROM AUTHOR] |
| Copyright of European Child & Adolescent Psychiatry is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Stimulant medication is effective in alleviating overall symptom severity of attention-deficit/hyperactivity disorder (ADHD), yet interindividual variability in treatment response and tolerability still exists. While network analysis has identified differences in ADHD symptom relations, the impact of stimulant medication remains unexplored. Increased understanding of this association could provide valuable insights for optimizing treatment approaches for individuals with ADHD. In this study, we compared and characterized ADHD symptom networks (including 18 ADHD symptoms) between stimulant-treated (n = 348) and untreated (n = 70) individuals with ADHD and non-ADHD controls (NACs; n = 444). Moreover, we compared symptom networks between subgroups defined by their stimulant treatment trajectory (early-and-intense use, late-and-moderate use). Stimulant-treated individuals with ADHD showed stronger associations between symptoms, compared with untreated individuals with ADHD and NACs. We found no differences in symptom networks between the stimulant treatment trajectory subgroups. Prospective longitudinal studies are needed to disentangle whether the identified differences stem from treatment or pre-existing factors. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 10188827 |
| DOI: | 10.1007/s00787-024-02610-8 |
